​

NRx Pharmaceuticals Stock (NASDAQ:NRXP)

ForecastRevenueOwnershipFinancialsChartTranscripts
NRx Pharmaceuticals by TradingView

Previous Close

$2.88

52W Range

$1.10 - $6.01

50D Avg

$2.82

200D Avg

$2.54

Market Cap

$55.05M

Avg Vol (3M)

$324.99K

Beta

1.64

Div Yield

-

NRXP Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Dec 04, 2017

Website

NRXP Performance

NRXP Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.50M$-27.59M$-44.40M
Net Income$-25.13M$-30.15M$-35.23M
EBITDA$-18.50M$-30.02M$-39.75M
Basic EPS$-2.39$-3.98$-0.54
Diluted EPS$-2.39$-3.98$-0.54

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 20, 25 | 8:00 AM
Q1 25May 16, 25 | 4:30 PM
Q4 24Mar 17, 25 | 8:30 AM

Peer Comparison

TickerCompany
LGVNLongeveron Inc.
BFRIBiofrontera Inc.
VRPXVirpax Pharmaceuticals, Inc.
SABSSAB Biotherapeutics, Inc.
ISPCiSpecimen Inc.
PTPIPetros Pharmaceuticals, Inc.
KTTAPasithea Therapeutics Corp.